leadf
logo-loader
viewRecce Pharmaceuticals Ltd

Recce Pharmaceuticals on track to develop synthetic antibiotics targeting superbugs

Recce Pharmaceuticals Ltd (ASX:RCE) executive director James Graham tells Proactive Investors the company is on the verge of developing a new class of synthetic antibiotics to counter antibiotic resistance.
 
As fears of superbugs may one day reach pandemic proportions, Graham says there hasn’t been a new class of antibiotics developed in decades.
 
Having received some global recognition, Recce fast-tracked regulatory review and has completed animal trials, with human studies soon to come, in Australia.

Quick facts: Recce Pharmaceuticals Ltd

Price: 1.635 AUD

ASX:RCE
Market: ASX
Market Cap: $238.8 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Recce Pharmaceuticals Ltd named herein, including the promotion by the Company of Recce Pharmaceuticals Ltd in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

AVZ Minerals strengthens financing discussions after boosting equity stake...

AVZ Minerals Ltd's (ASX:AVZ) Nigel Ferguson speaks to Proactive's Andrew Scott after announcing they've executed a share purchase agreement (SPP) to secure an additional 10% of Dathcom Mining SA from its JV partner, Dathomir Mining Resources SARLU, the 100% holder of the Manono Lithium and Tin...

32 minutes ago

2 min read